The longstanding problem of rapid inactivation of the glycolytic pathway in skeletal muscle after contraction was investigated using 31 P NMR spectroscopy and computational modelling. Accumulation of phosphorylated glycolytic intermediates (hexose monophosphates) during cyclic contraction and subsequent turnover during metabolic recovery was measured in vivo in human quadriceps muscle using dynamic 31 P NMR spectroscopy. The concentration of hexose monophosphates in muscle peaked 40 s into metabolic recovery from maximal contractile work at 6.9 ± 1.3 mm (mean ± s.d.; n = 8) and subsequently declined at a rate of 0.009 ± 0.001 mm s −1 . It was next tested whether the current knowledge of the kinetic controls in the glycolytic pathway in muscle integrated in the Lambeth and Kushmerick computational model of skeletal muscle glycolysis explained the experimental data. It was found that the model underestimated the magnitude of deactivation of the glycolytic pathway in resting muscle, resulting in depletion of glycolytic intermediates and substrate for oxidative ATP synthesis. Numerical analysis of the model identified phosphofructokinase and pyruvate kinase as the kinetic control sites involved in deactivation of the glycolytic pathway. Ancillary 100-fold inhibition of both phosphofructokinase and pyruvate kinase was found necessary to predict glycolytic intermediate and ADP concentrations correctly in resting human muscle. Incorporation of this information into the model resulted in highly improved agreement between predicted and measured in vivo dynamics of hexose monophosphates in muscle following contraction. We concluded that silencing of the glycolytic pathway in muscle following contraction is most likely to be mediated by phosphofructokinase and pyruvate kinase inactivation on a time scale of seconds and minutes, respectively, and is necessary to prevent depletion of vital cellular substrates.
The longstanding problem of rapid inactivation of the glycolytic pathway in skeletal muscle after contraction was investigated using 31 P NMR spectroscopy and computational modelling. Accumulation of phosphorylated glycolytic intermediates (hexose monophosphates) during cyclic contraction and subsequent turnover during metabolic recovery was measured in vivo in human quadriceps muscle using dynamic 31 P NMR spectroscopy. The concentration of hexose monophosphates in muscle peaked 40 s into metabolic recovery from maximal contractile work at 6.9 ± 1.3 mm (mean ± s.d.; n = 8) and subsequently declined at a rate of 0.009 ± 0.001 mm s −1 . It was next tested whether the current knowledge of the kinetic controls in the glycolytic pathway in muscle integrated in the Lambeth and Kushmerick computational model of skeletal muscle glycolysis explained the experimental data. It was found that the model underestimated the magnitude of deactivation of the glycolytic pathway in resting muscle, resulting in depletion of glycolytic intermediates and substrate for oxidative ATP synthesis. Numerical analysis of the model identified phosphofructokinase and pyruvate kinase as the kinetic control sites involved in deactivation of the glycolytic pathway. Ancillary 100-fold inhibition of both phosphofructokinase and pyruvate kinase was found necessary to predict glycolytic intermediate and ADP concentrations correctly in resting human muscle. Incorporation of this information into the model resulted in highly improved agreement between predicted and measured in vivo dynamics of hexose monophosphates in muscle following contraction. We concluded that silencing of the glycolytic pathway in muscle following contraction is most likely to be mediated by phosphofructokinase and pyruvate kinase inactivation on a time scale of seconds and minutes, respectively, and is necessary to prevent depletion of vital cellular substrates. Excitable cells, such as skeletal muscle fibres, may undergo rapid and large (up to two orders of magnitude) transitions in ATP turnover rate upon activation (Blei et al. 1993; Walter et al. 1999) . To buffer and balance this large dynamic capacity for ATP utilization, excitable cells contain multiple ATP synthetic pathways, including glycolysis and mitochondrial oxidative phosphorylation (Blei et al. 1993; Walter et al. 1999) . These pathways and their kinetic controls have been extensively investigated and characterized to the point that detailed in silico models are now available (Magnus & Keizer, 1997; Vicini & Kushmerick, 2000; Lambeth & Kushmerick, 2002; Beard, 2005; Dash et al. 2008; Selivanov et al. 2008) . Conversely, these computational models offer powerful quantitative tools for rigorous testing of the sufficiency and consistency of current understanding and formulation of cellular ATP synthesis and its regulation (Beard et al. 2005) . A specific concern is the fact that the majority of the information captured by these models has come from in vitro determinations of enzyme kinetics (Teusink et al. 2000; Beard et al. 2005) . However, in the living cell, ancillary interactions (e.g. protein-protein interactions, Frieden, 1971; or substrate channelling, Winkel, 2004 ) may greatly influence pathway behaviour. For example, it has been documented that the activity of phosphofructokinase (PFK), a key regulatory enzyme in the glycolytic pathway, is regulated by attachment to the cellular cytoskeletal matrix in addition to classic metabolic regulation by AMP, ADP and inorganic phosphate (P i ; Lilling & Beitner, 1991; Marinho-Carvalho et al. 2006; Marinho-Carvalho et al. 2009 ). Any incorporation of this information into the available computational models of glycolysis, however, has been lacking (Lambeth & Kushmerick, 2002; Dash et al. 2008; Selivanov et al. 2008) . As such, it remains to be tested if and how much the latter type of 'physiological' metabolic regulation (as opposed to 'biochemical' regulation by metabolite concentrations) contributes to pathway flux and concentration control in vivo.
In the case of glycolysis, there is, in fact, a clear and pressing need for such a test. It has long been known that glycolytic flux in skeletal muscle is arrested in noncontracting muscle even in the presence of elevated concentrations of the classic metabolic regulators, AMP, ADP and P i . This observation was first made almost 30 years ago (Dawson et al. 1980) and has since been independently confirmed (Taylor et al. 1983; Quistorff et al. 1993; Wackerhage et al. 1998; Crowther et al. 2002a,b) . Hypotheses explaining this surprising finding all invoke inactivation of key glycolytic enzymes, such as PFK, via some relaxation-related mechanism (e.g. a drop in cytoplasmic Ca 2+ ; Dawson et al. 1980; Crowther et al. 2002a,b) . However, biochemical details, including sites, magnitude and mechanism of pathway inactivation as well as the physiological significance for the resting skeletal muscle state all remain to be discovered.
Here, the kinetic controls involved in shutting down glycolysis in non-contracting skeletal muscle and its physiological significance for the resting skeletal muscle state are investigated using a combination of experimental and computational investigative approaches. First, we performed high time resolution dynamic in vivo measurements of the turnover of phosphorylated glycolytic metabolites (hexose monophosphates; HMP) in human leg muscle after exhaustive exercise using 31 P NMR spectroscopy. Next, the Lambeth & Kushmerick computational model of glycolysis in muscle was used as a platform to investigate whether current knowledge of glycolytic flux and concentration control incorporated in the model was sufficient to explain the measured HMP dynamics (Lambeth & Kushmerick, 2002) . Finally, computational strategies, including network analysis, were used to identify the kinetic control sites in the glycolytic pathway involved in shutting down glycogen turnover in the postexercise state and to investigate its significance for the resting skeletal muscle state. It was found that inactivation of both PFK and pyruvate kinase (PK) are necessary components of the metabolic regulation underlying the silencing of glycolysis in resting skeletal muscle to prevent depletion of vital cellular substrates.
Methods

Nuclear magnetic resonance experiments
Ethical approval. Eight normally active, healthy male subjects (mean age 26 years; range 22-45 years) participated in the study. The nature and the risks of the experimental procedures were explained to the subjects, and all gave their written informed consent to participate in the study, which conformed to the standards set by the Declaration of Helsinki and was approved by the local Medical Ethical Committee of the Máxima Medical Center, Veldhoven, The Netherlands. All subjects wore shorts and athletic shoes during the examination. 31 P NMR spectroscopy. All measurements were performed on a 1.5 T whole body scanner (Gyroscan S15/ACS, Philips Medical Systems, Best, The Netherlands) equipped with a custom-built non-ferrous, mechanically braked bicycle ergometer. Details of the ergometer, its interfacing with the spectrometer for gated acquisition during bicycling exercise, subject positioning and familiarization with the exercise are described in detail elsewhere (Jeneson et al. 2010) . A single-turn 31 P surface coil (diameter 6 cm) supplied by the manufacturer was positioned over the medial head of the quadriceps muscle of the right leg and fastened with Velcro. The magnet was shimmed using a custom-built rectangular 1 H surface coil (20 cm × 10 cm) positioned over the quadriceps muscle as described elsewhere (Jeneson et al. 2010) . All 31 P NMR spectra were acquired using a 90 deg adiabatic excitation pulse. Prior to the exercise bout, two 31 P spectra [16 summed free induction decays (FIDs); 1024 points; sweep width 2 kHz] were obtained from the resting muscle in the resting position under fully relaxed (TR 15 s) and partly saturated experimental conditions (TR 3 s) to determine saturation correction factors for each resonance. Next, subjects performed a bicycling ramp exercise bout consisting of three incremental workloads, including maximal workload (1, 2 and 3 kg braking load, respectively). The pedalling rate was 80 r.p.m., set by a metronome. Each workload was maintained for 144 s, during which four 31 P NMR spectra (12 summed FIDs) were collected from the muscle. During the first 108 s of metabolic recovery after completion of the exercise test, 31 P NMR spectra consisting of four summed FIDs were serially collected, yielding a time resolution of 12 s. In the second phase of recovery, the time resolution was decreased to 36 s (12 summed FIDs per spectrum). The total scan time was 846 s (432 s during exercise and 414 s during recovery, respectively). Fifteen minutes after exercise had ended, the subjects performed a second, less intense incremental workload test, from which the data were not used, except for the first spectrum, which provided an additional data point in the HMP recovery dynamics.
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Data processing. Spectra were fitted in the time domain by using a non-linear least-squares algorithm (AMARES) in the jMRUI software package (Vanhamme et al. 1997) . Phosphate mono-esters (PME), P i , phosphocreatine (PCr) and ATP signals were fitted to Lorentzian line shapes. The three ATP peaks were fitted as two doublets and one triplet, with equal amplitudes and line widths and prior knowledge for the J-coupling constant (17 Hz). Maximal line widths were constrained at 30 Hz. Absolute concentrations of the metabolites were calculated after correction for partial saturation and assuming that the ATP concentration ([ATP]) is 8.2 mM at rest (Taylor et al. 1986) . Intracellular pH was calculated from the chemical shift difference between the P i and PCr resonances (δ; measured in parts per million) according to the following equation (Tobin et al. 1972) :
Computational modelling
Design of the numerical analysis. The primary purpose of the computational part of this study was to investigate the mechanisms involved in the observed HMP dynamics during metabolic recovery from exercise. The analysis also required information that was obtained by performing a simulation in two additional conditions, namely high ATP demand flux and rest. The glycolytic pathway substrate supply flux was assumed to be different for each of the three following conditions. (1) In the metabolic recovery conditions, substrate for the glycolytic pathway supply was provided by glucose phosphorylation by hexokinase (HK) concomitant with net glycogen synthesis. The model for this particular condition will be referred to as the 'recovery condition model' (Fig. 1A) . (2) In the condition of high ATP demand (i.e. during exercise), pathway substrate supply was assumed to be provided by net glycogen breakdown; the relative contribution of glucose phosphorylation by hexokinase was assumed to be negligible. The pathway model for this particular condition is the original Lambeth and Kushmerick model (Fig. 1B) . (3) In steady-state rest conditions (i.e. with respect to ATP metabolism), it was assumed as a first approximation that no net glycogen production occurred, and pathway supply was provided by glucose phosphorylation through hexokinase. The pathway model in this particular condition will be referred to as the 'resting condition model' (Fig. 1C) .
The Lambeth and Kushmerick model of muscle glycolysis (Lambeth & Kushmerick, 2002 ) was used as a platform to perform the numerical analyses. This model was parameterized with data of mammalian skeletal muscle origin, except for the phosphoglycerate mutase parameters, which were obtained from chicken skeletal muscle. Minor adaptations were made to model conditions 1 and 3 described above. A schematic representation of the adapted models is shown in Fig. 1A and C. The flux equations, initial conditions and parameter values have been described previously by Lambeth & Kushmerick (2002) ; in the subsections below we restrict the description to the details of model adaptations. The computational models were implemented using Matlab 7.5.0 (the Mathworks Inc., Natick, MA, USA). Differential equations were numerically solved using ODE15s. The model did not take mitochondrial dynamics into account. The ATPase flux that was set in the model therefore corresponded only to the part that was matched by glycogenolytic ATP production.
The Lambeth and Kushmerick model of glycogenolysis in mammalian skeletal muscle was parameterized using information on rabbit and pig muscle enzyme kinetics reported by Scopes (1973) . Here, the model was applied to analyse human muscle data. The effect of possible differences in kinetic properties and concentrations of glycolytic enzymes in human muscle versus rabbit and pig muscle on model predictions was probed by performing model simulations in a Monte Carlo approach.
Estimation of ATPase flux rate. In resting conditions, ATP is mainly produced by mitochondria, whereas the glycolytic pathway accounts for only a minor part of the total ATP production flux. The ATPase flux in resting human skeletal muscle tissue was reported by Blei et al. (1993) to be 8 ± 2 μM s −1 (n = 5). The part of the ATPase flux that was accounted for by glycolytic ATP production was calculated. Assuming that mitochondria synthesize 30 mol of ATP per mole of glucose and that glycolysis has a net yield of 2 mol ATP per mole of glucose (Brand, 2005) , glycolytic flux would account for 1/15 part of the total ATPase flux in conditions when mitochondria rely solely upon pyruvate as substrate. However, in resting conditions the muscle mitochondria also oxidize significant amounts of fatty acids. Reported values for the percentage of fatty acid utilization vary between 30 and 60% (Jensen et al. 1998; Bradley et al. 1999; Bergman et al. 1999a) . To include this effect and take into account some additional uncertainties due to unknown fluxes through other pathway branches, the glycolytic ATP production flux at rest was estimated to be within the range of 0.10-0.75 μM s −1 . This range is in accordance with literature values of leg glucose uptake (0.05-0.35 mM min −1 per limb; Snyder et al. 1975; Katz et al. 1986; Bergman et al. 1999b; Durham et al. 2004; Enevoldsen et al. 2005 ) that were converted by assuming that a leg has between 7 and 10 kg of muscle mass (Snyder et al. 1975) . Blei et al. (1993) reported the ATPase rate in resting skeletal muscle; however, it remains unknown to what extend this value is also valid for skeletal muscle during recovery conditions. To include this uncertainty in the analysis, the ATPase during recovery was estimated to be within a range of 0.1-10 times the normal resting muscle ATPase activity, which sets the range for ATPase during recovery conditions to 0.0001-0.01 mM s −1 .
Model analysis of recovery dynamics
Model adaptations. The model used to simulate recovery conditions featured a net glycogen production and glucose phosphorylation by hexokinase (recovery condition model; Fig. 1A ). Development of a kinetic model of the glycogen production pathways was beyond the scope of this study. Instead, net glycogen production was modelled by deleting glycogen phosphorylase flux and substituting it with a net glycogen production flux. Glucose phosphorylation is inhibited at high concentrations of glucose 6-phosphate (G6P). As a consequence, G6P supply flux by hexokinase could not be modelled as a constant during the recovery period; 
0.069 mM therefore, a kinetic model of hexokinase was included.
Hexokinase was modelled according to the description of Gerber et al. (1974) as follows:
Although this model was developed for a different cell type, i.e. human erythrocytes, this description was used because the same isozyme is also predominant in skeletal muscle tissue (Wilson, 1995) . The ATPase flux equation was simplified compared with the original model. The mass action equation used by Lambeth & Kushmerick (2002) was substituted by a single parameter (unit mM s −1 ), which effectively clamped ATPase flux at a certain, adjustable level.
Model parameterization. The model adaptations introduced a few new parameters: kinetic parameters of hexokinase, glycogen production flux and ATPase flux. All other parameters were left unchanged from the original paper of Lambeth & Kushmerick (2002) .
Hexokinase kinetic parameter values are listed in Table 1 . Intracellular glucose concentration was clamped at 3 mM, according to measurements of Katz et al. (1986) , who reported that glucose concentration remained stable during at least the first 10 min of recovery following an exhaustive bicycle exercise bout. The value of V respectively.
The glycogen production flux (unit μM s −1 ) after a glycogen-depleting exercise bout was measured by Price et al. (1994) . From these results the glycogen production flux was estimated to be within a range of 0-0.75 μM s −1 . The ATPase during recovery was estimated to be within a range of 0.1-10 times the normal resting ATPase activity, which sets the range for ATPase during recovery conditions to 0.0001-0.01 mM s −1 . The model V max parameters were set by Lambeth & Kushmerick (2002) according to the data of Scopes (1973) . Since these parameters were not specifically set for human quadriceps muscle, uncertainties with respect to these values were also taken into account. The V max values of glycolytic enzymes were assumed to be within a range of 25-175% of the value determined by Scopes (1973) . This range was set based upon comparison of glycolytic enzyme activities determined for multiple species: rabbit, pig, rat and human Scopes, 1973) .
Lactate efflux (LAC eff ) was modelled by a mass action flux, with parameter K Lac set to 0.01 s −1 , as follows:
where [Lac] is the concentration of lactate.
Initial conditions. During the first phase of recovery, PCr was resynthesized by mitochondrial function. These dynamics were accompanied by P i , ADP and AMP concentrations that dropped to resting levels. Inorganic phosphate, ADP and AMP are important substrates and regulators of the glycolytic pathway. The mitochondria exert control on the P i , ADP and AMP dynamics and thus indirectly on the dynamics of the glycolytic pathway.
Modelling glycolysis during the full recovery period would therefore require the inclusion of a model of mitochondrial function. Instead of adding even more complexity to the model, we choose a different solution. The first 60 s of data were excluded, which restricted our analysis to the data where PCr, P i , ADP and AMP were close to resting levels. The selected data analysed with the computational model are indicated in Fig. 3 . All initial conditions were left unchanged from the paper by Lambeth & Kushmerick (2002) , except for the initial conditions of glucose 1-phosphate (G1P), G6P and fructose 6-phosphate (F6P) concentrations, which were set according to the experimental NMR data. The PME detected in the NMR spectra was used to calculate the concentration of HMP, which represents the sum of G1P, G6P and F6P (Dawson et al. 1980; Walter et al. 1999) . Individual G1P, G6P and F6P concentrations were calculated by assuming that phosphoglucomutase and phosphoglucoisomerase were close to equilibrium (Rolleston & Newsholme, 1967; Eanes et al. 2006) . Calculated values for initial concentrations of G1P, G6P and F6P were 0.26, 4.37 and 1.96 mM, respectively.
Model simulations. For the glycogen production flux and the ATPase rate and glycolytic enzyme V max values, we determined a range rather than a precise value. We used a Monte Carlo approach to perform simulations for these parameter distributions. Uniform distributions were assumed within the determined range. Five thousand simulations were run, randomly drawing parameter values from the distributions. As a result, the computational model predicted a solution space (mean ± S.D. of 5000 simulations) indicating the influence of the width of the distributions on the accuracy of the model predictions. It was tested whether 5000 simulations were enough to obtain stable predictions for the solution space of the model. To this end, the solution space calculated based upon 5000 simulations was compared with the result obtained with 1000 simulations. These results were similar, indicating that 5000 simulations were enough to provide stable predictions.
Maximal glycolytic ATP production capacity
We calculated the maximal glycolytic ATP production capacity, which was defined as the maximal ATP production flux the model can generate while state variables remain within a physiological domain. During maximal activation of the glycolytic pathway, the pathway substrate supply is primarily provided by glycogen breakdown. These conditions were modelled by the original Lambeth and Kushmerick model (Fig. 1B) . Therefore, the Lambeth and Kushmerick model was used to calculate the maximal pathway flux (pathway V max ).
Maximal pathway flux was calculated by performing a series of simulations, incrementally increasing the ATPase rate with a step size of 0.01 mM s −1 . All simulations were run until glycolytic ATP production and ATPase fluxes were balanced and steady state was reached. The free energy of cytoplasmic ATP hydrolysis ( G p ) was calculated according to the following equation (Jeneson et al. 1996) :
where G o p is −32.8 kJ mol −1 at 37 • C (Rosing & Slater, 1972) .
Previous studies indicated that if G p increased above −48 kJ mol −1 , excitation-contraction coupling failed (Hancock et al. 2005) . This information was used to constrain the computational dynamic range of the model. If G p increased above −48 kJ mol −1 , simulations went out of the physiological range and the incremental increase of ATPase flux was ended. The ATPase flux at which the simulations were ended was then defined as the maximal glycolytic ATP production capacity.
Identification of control points
We analysed which enzymes exerted most of the concentration control in resting conditions. To this end, resting state model predictions (resting condition model; Fig. 1C ) were compared with data in the literature on the resting concentration in skeletal muscle of a selected subset of metabolites relevant to the model: ADP, G6P and fructose 1,6-bisphosphate (F-1,6P 2 ).
In resting state conditions, it was assumed that no net glycogen production or consumption was present. This was modelled by deleting the glycogen phosphorylase flux from the original model of Lambeth and Kushmerick. The resting state ATPase flux that was met by glycogenolytic ATP production was, as described in the subsection 'Estimation of ATPase flux rate' , estimated to be between 0.1 and 0.75 μM s −1 . In steady-state conditions, glycolytic pathway substrate supply, glycolytic ATP production and ATPase flux are in balance. Glycolysis yields two molecules of ATP per glucose molecule. This stochiometry, combined with the requirement of steady-state conditions, determine that glucose phosphorylation flux is balanced to ATPase flux according to the following equation:
This relation was used to set the G6P supply flux in these steady-state simulations. The concentration control of individual glycolytic enzymes on the concentration of the selected metabolites, ADP, G6P and F-1,6P 2 , was calculated by performing a series of simulations. For each simulation, a different glycolytic enzyme was inhibited, by multiplying the V max of that specific enzyme by 0.05, and differences in the steady-state values of glycolytic intermediates were compared. Figure 2 shows a selection of 31 P NMR spectra from a large dynamic set acquired from the quadriceps muscle at rest ( Fig. 2A) , during exercise at maximal workload (Fig. 2B ) and during metabolic recovery (Fig. 2C and D) . At the end of the incremental exercise bout, the PCr pool was nearly depleted, accompanied by a complementary increase in P i . During bicycling at the maximal workload, a significant PME resonance appeared up-field of the P i resonance that was attributed to accumulating phosphorylated glycolytic intermediates (HMP) in contracting muscle fibres (Walter et al. 1999; Dawson et al. 1980) . During the subsequent metabolic recovery, P i and PCr returned to resting levels within 60 s. The PME resonance, however, exhibited much slower dynamics and was still clearly observed 240 s into recovery. The striking accumulation of HMP is most clearly observed during recovery due to the downfield shift of the P i resonance as a result of rapid ancillary muscle acidification (Fig. 2C  and D) .
The quantified, pooled results of the 31 P NMR measurements in eight muscles are shown in Fig. 3 . The PCr concentration decreased from 32.2 ± 3.0 mM (mean ± S.D.; n = 8) at rest to 5.9 ± 3.2 mM at the end of the high-intensity exercise bout, while P i increased from 4.8 ± 0.8 to 26.8 ± 3.5 mM (Fig. 3A) . Accumulation of HMP started during exercise at the highest workload and peaked at 6.9 ± 1.3 mM 42 s into recovery, after which a slow but steady consumption (0.009 ± 0.001 mM s −1 ) was observed (Fig. 3B) . The HMP concentration, quantified from a spectrum obtained 15 min after the end of exercise, had returned to the resting level (1.1 ± 0.4 mM; data point not shown in Fig. 3) . The ATP and total phosphate pool levels remained stable within 10% of resting values throughout the entire protocol (8.2 and 47 mM, respectively; Fig. 3C ). Intramuscular pH decreased 0.3 units during the exercise bout from 7.08 ± 0.02 at rest to 6.75 ± 0.05 at maximal workload (Fig. 3D ). This moderate drop in muscle pH during exercise indicated that the muscle remained well perfused during the entire exercise protocol and that lactate and CO 2 were to a great extent washed out of the muscle tissue (Jeneson & Bruggeman, 2004) . During the initial phase of recovery, pH dropped another 0.3 units to 6.46 ± 0.11 as a result of rapid consumption of proton buffer (i.e. P i ; Jeneson & Bruggeman, 2004) and recovered slowly towards the resting value (Fig. 3D ). Figure 4 shows the result of the simulation of the recovery dynamics of all twelve glycolytic intermediate metabolites of the model. The results show the mean ± S.D. of the 5000 simulations that were performed in the Monte Carlo approach to account for uncertainties in the model parameter values. In this approach, parameter values for the ATPase rate, the glycogen consumption and V max parameters of glycolytic enzymes were selected randomly from a uniform distribution with ranges 0.0001-0.01 mM s −1 , 0-0.75 μM s −1 and 25-175% of the values reported by Scopes (1973) , respectively. The HMP dynamics (sum of G1P, G6P and F6P; Dawson et al. 1980; Walter et al. 1999) were calculated from the model simulations and compared with the experimental data (Fig. 5) . The predicted HMP consumption rate was two orders of magnitude faster than the experimentally determined rate (0.57 versus 0.009 ± 0.001 mM s −1 , respectively). This HMP consumption rate was accompanied by a rapid accumulation of fructose 1,6-bisphosphate and glyceraldehyde 3-phosphate (GAP) to levels of 3.4 and 2.5 mM, respectively, and a peak in lactate production. All other state variables remained at relatively stable levels.
Model simulations of recovery dynamics
Maximal glycolytic ATP production capacity
It was next tested whether the overly fast kinetics of the recovery conditions model were the trivial result of the maximal glycolytic ATP production capacity of the model exceeding reported experimental values. The maximal glycolytic ATP production of the computational model was calculated to be 1.4 mM s −1 as described in the Methods section. This value agreed well with the rate reported for a type I muscle fibre and was about half the value reported for a type II muscle fibre (1.5 and 3.0 mM s −1 , respectively; Greenhaff et al. 1994) . From these results, we concluded that two orders of magnitude faster consumption of HMP predicted by the model (Fig. 5) was not a trivial result. Table 2 and indicated as shaded areas in Fig. 6 . From these results, it followed that the model converged at a non-physiological steady state without additional enzyme inhibition, indicating inadequate concentration control. Model simulations predicted a nearly full depletion of G6P and F-1,6P 2 to levels of 0.0094 and 0.00028 mM, respectively, whereas reported values range between 0.24-0.82 mM and 0.04-0.06 mM, respectively (Essen & Kaijser, 1978; Katz et al. 1986; Katz & Lee, 1988; Greenhaff et al. 1994) . Likewise, [ADP] fell to a twofold lower value than the consensus value in the absence of additional flux inhibition (0.0050 versus 0.010 mM; Walter et al. 1999; Chen et al. 1999; Roef et al. 2002; van den Broek et al. 2007 ). Steadystate metabolite concentrations calculated for the case of selective ancillary enzyme inhibition by 95% showed that [G6P] was increased by inhibition of PFK and that [F-1,6P 2 ] was increased by inhibition of PK. The steady-state [ADP] was affected by 95% inhibition of both PFK and PK.
Identification of control points
Parameterization of PFK and PK inhibition factors
We next hypothesized that additional inhibition of PFK and PK in electrically silent skeletal muscle must be present. Hereto, inhibition factors in the form of V max scalars for PFK and PK were introduced into the model. Parameterization of these inhibition factors was performed based upon reported values of [G6P] and Table 3 .
It was then tested whether introduction of the PFK and PK inhibition factors caused other state variables to go out of their physiological range. Hereto, the steadystate metabolite concentrations were calculated for four cases: (1) no additional inhibition; (2) inhibition of PFK and PK; (3) inhibition of PFK; and (4) inhibition of PK. Steady-state metabolite concentrations were determined using a Monte Carlo approach. Parameter distributions were assumed for PFK inhibition factor (0.0037-0.030; Table 3 ), PK inhibition factor (0.0027-0.021; Table 3) .0e-05 a 1.13 × 10 -6 ± 2.5 × 10 -8 6.49 × 10 -6 ± 6.94 × 10 -6 2.82 × 10 -6 ± 1.11 × 10 -6 6.47 × 10 -6 ± 7.75 × 10 -6 P i 4. Steady-state metabolite concentrations were calculated for four cases: (1) no additional inhibition (original model); (2) PFK and PK inhibition; (3) PFK inhibition; and (4) PK inhibition. * Improved model prediction as a result of PFK and PK inhibition. †Improved model prediction as a result of PFK inhibition. ‡Improved model prediction as a result of PK inhibition. a See references: Arnold & Pette (1968) ; Harris et al. (1974); Sahlin (1985) ; Cheetham et al. (1986) . b Concentration unreported for skeletal muscle. Estimated values are based upon orders of magnitude seen in other cell types. Abbreviations: G1P, glucose-1-phospate; G6P, glucose-6-phospate; F6P, fructose 6-phospate; F1,6P 2 , fructose 1,6-biphosphate; DHAP, dihydroxyacetone-phosphate; GAP, glyceraldehyde-3-phosphate; 13BPG, 1,3-bisphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP, phosphoenolpyruvate; PYR, pyruvate; LAC, lactate; PCr, phosphocreatine; ADP, adenosine diphosphate; Cr, creatine; ATP, adenosine triphosphate; Pi, inorganic phosphate; AMP, adenosine monophosphate; NAD, nicotinamide adenine dinucleotide.
Effect of PFK and PK deactivation on recovery dynamics
Metabolite concentration dynamics during recovery were calculated for the adapted model featuring PFK and PK deactivation mechanisms and are shown in Fig. 7 . The shaded area represents the mean ± S.D. of 5000 simulations that were run in a Monte Carlo approach. Parameter distributions were assumed for glycogen production flux (0-0.75 μM s −1 ), ATPase rate (0.01-0.0001 mM s −1 ), PFK inhibition factor (0.0037-0.030; Table 3 ), PK inhibition factor (0.0027-0.021; Table 3 ) and V max parameters of glycolytic enzymes (25-175% of the value reported by Scopes, 1973) . Recovery dynamics were calculated for the case of both PFK and PK inhibition (Fig. 7) and PFK inhibition only (Fig. 8) Fig. 9A and B, respectively. These results showed that model predictions of HMP dynamics in both cases agreed well with the experimental data. Compared with the predictions of HMP dynamics according to the model without inhibition (Fig. 5) , a clear improvement between simulated HMP dynamics and experimental HMP data was observed. Figure 9C and D shows the model predictions of steady-state [G6P], [F-1,6P 2 ] and [ADP] relative to the literature value, in the case of PFK and PK deactivation ( Fig. 9C ) and only PFK inhibition (Fig. 9D) . The results were normalized by dividing model predictions by the reported literature value. The horizontal black line represents the target value of 1, which corresponds to
Figure 7. Simulations of recovery dynamics of glycolytic intermediate metabolites performed with the model that included PFK and PK inhibition
The solution space (shaded area) is indicated by the mean ± S.D. of the 5000 simulations that were run in a Monte Carlo approach. Abbreviations: G1P, glucose-1-phospate; G6P, glucose-6-phospate; F6P, fructose 6-phospate; F1,6P 2 , fructose 1,6-biphosphate; DHAP, dihydroxyacetone-phosphate; GAP, glyceraldehyde-3-phosphate; 13BPG, 1,3-bisphosphoglycerate; P3G, 3-phosphoglycerate; P2G, 2-phosphoglycerate; PEP, phosphoenolpyruvate; PYR, pyruvate; LAC, lactate.
the ideal situation of a perfect agreement between the literature value and model prediction. The results show that in case of only PFK deactivation, the model failed to correctly predict [F-1,6P 2 ] at steady state, indicating that both PFK and PK deactivation must be present in resting skeletal muscle.
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Finally, it was investigated whether inhibition of all glycolytic enzymes other than PFK and PK by 99% or reduced inhibition of PFK and PK (80% inhibition) could produce similar results. In either case, the HMP dynamics were similar to the original model and did not agree with experimental data (data not shown).
Figure 8. Simulations of recovery dynamics of glycolytic intermediate metabolites performed with the model that included PFK inhibition
Discussion
The main and novel result of the present investigation of muscle glycolysis was the identification of a principal role for the regulation of PFK and PK activity in the silencing of glycolytic flux in non-contracting muscle. These results and possible biochemical and physiological regulatory mechanisms that may be involved in PFK and PK activity control are discussed together with several methodological aspects of the study.
Experimental observations
The dynamics observed in the PME domain of the NMR spectrum were attributed to G6P, F6P G1P and conform to previous studies (Dawson et al. 1980; Walter et al. 1999) . The accumulation of G6P observed during the high-intensity in-magnet exercise protocol agreed with measurements based upon the analysis of muscle biopsy samples obtained after high-intensity dynamic exercise (Essen & Kaijser, 1978; Katz et al. 1986; Sahlin et al. 1987; Greenhaff et al. 1994) . Essen & Kaijser (1978) collected five biopsy samples during the first 180 s of the recovery period to determine the [G6P] dynamics. They also reported [G6P] peaks after about 30 s (Essen & Kaijser, 1978) . Moreover, the measured Table 2. rate of G6P consumption (0.007 ± 0.001 mM s −1 ) agreed well with the rate that we determined non-invasively by 31 P MRS (0.006 ± 0.001 mM s −1 ). The G6P consumption rate was obtained by applying the computational model to decompose the measured HMP consumption rate (0.009 ± 0.001 mM s −1 ) by predicting individual G6P (0.007 ± 0.001 mM s −1 ), G1P (0.0004 ± 0.0002 mM s −1 ) and F6P (0.003 ± 0.002 mM s −1 ) consumption rates.
Model parameterization
The Lambeth and Kushmerick model of muscle glycogenolysis, like the majority of computational models of metabolism (e.g. Beard, 2005; Dash et al. 2008) , contains specific values for all model parameters. The lack of information on the exact value of the ATP consumption and glycogen synthesis rates in human quadriceps muscle during recovery following exhaustive exercise, as well as the postulated PFK and PK inhibition factors, however, warranted the use of an alternative approach in the Exp Physiol 95.2 pp 380-397 present study. Instead of single values, simulations of our adapted model of muscle glycogenolysis were performed using a range of values for this particular subset of the model parameters. This allowed investigation of the sensitivity of the model predictions to uncertainties in the value of each of these model parameters. Indeed, the predictions of HMP dynamics by the tested adaptations of the Lambeth and Kushmerick model that included additional PFK and PK inhibition were sensitive to these uncertainties ( Fig. 9A and B) . However, the resulting solution space was still sufficiently narrow to allow for detection of any improvement of the model predictions after inclusion of the postulated additional strong PFK and PK inactivation in non-contracting muscle. This improvement was attributed to the addition of the PFK inhibition factor; not including PK inhibition did not affect predicted HMP dynamics ( Fig. 9A and B) . The comparison of HMP model predictions and experimental data provides validation of the model adaptations with respect to PFK inhibition. Previous studies of the silencing of glycolysis in resting muscle have proposed direct or indirect (i.e. via a kinase/phosphatase network) inactivation of key glycolytic enzymes by a drop in intracellular Ca 2+ to explain their experimental observations. Alternatively, PFK deactivation may be explained by detachment from the cytoskeleton (Lilling & Beitner, 1991; MarinhoCarvalho et al. 2006 MarinhoCarvalho et al. , 2009 ). Yet another possible mechanism may be related to pH. Specifically, Hand & Somero (1983) measured PFK activity as a function of pH at different temperatures in Spermophilus beecheyi. They found that at pH 6.8 (temperature 37
• C), there was no effect of pH on PFK inhibition (PFK activity 95% of V max ), whereas at pH 6.5 the PFK activity was nearly fully inhibited (PFK activity 5% of V max ). During the initial phase of recovery, pH dropped from 6.8 to 6.5 within seconds (Fig. 3) . As such, pH may have a regulatory function in the work-to-rest transitions. However, it cannot explain the deactivation of PFK in a normal resting skeletal muscle (pH 7.05) and therefore we concluded that a pH-related mechanism of PFK deactivation cannot be the primary mechanism.
Model adaptation: PK inhibition
Predictions of resting steady-state [F-1,6P 2 ] according to the model with only PFK inhibition were over ten thousand times smaller than experimentally determined. Computational analysis of the inhibition of individual glycolytic enzymes indicated that PK inactivation must be present in resting skeletal muscle tissue to rise the resting [F-1,6P 2 ]. However, no Ca 2+ -mediated PK inactivation mechanism has been reported. Model simulations of recovery dynamics of both PFK and PK inhibition and PFK inhibition alone showed no difference in predicted HMP dynamics; however, the [F-1,6P 2 ] dynamics were more affected. These predictions provide valuable information about the mechanisms of PK inhibition. Analysis of muscle biopsy samples taken after intense exercise showed only a twofold increase in [F-1,6P 2 ], from 0.05 to 0.1 mM (Essen & Kaijser, 1978; Katz & Lee, 1988) . Immediate inactivation of both PFK and PK predicted a solution space of [F-1,6P 2 ] accumulation larger than observed experimentally, whereas PFK inhibition alone predicted a solution space more consistent with the experimental data. These results indicated that PK inhibition is not present at the onset of the recovery period and the deactivating mechanism is not as fast as PFK inhibition and thus probably also not Ca 2+ mediated. Feedforward regulation of PK activity by [F-1,6P 2 ] is a well-known mechanism (Hall & Cottam, 1978; Fothergill-Gilmore & Michels, 1993; Valentini et al. 2000) that can explain the PK inhibition at rest. All mammalian PK isoenzymes are sensitive for allosteric regulation of F-1,6P 2 except for isoenzyme M1 (Hall & Cottam, 1978; Fothergill-Gilmore & Michels, 1993; Valentini et al. 2000) , which is the isoenzyme found in mammalian skeletal muscle tissue (Hall & Cottam, 1978; Fothergill-Gilmore & Michels, 1993; Valentini et al. 2000) . However, there is also evidence that a single amino acid substitution in the M1 isoenzyme can turn it into an allosteric regulated enzyme (Ikeda et al. 1997) . It is not inconceivable that, in in vivo conditions, other factors, e.g. metabolites and signalling molecules, cause a small conformation change which activates the allosteric regulation in the M1 isoenzyme. This investigation indicated that PK inhibition must occur in parallel with PFK inhibition, albeit on a much slower time scale. However, the underlying mechanism remains to be determined.
Silencing of glycolysis in muscle: hypothesis
The present finding of a slow HMP consumption rate in muscle in the postexercise state agreed well with the observation that in spite of high substrate (ADP and P i ) and activator levels (AMP), glycolytic flux is silenced in non-contracting muscle (Dawson et al. 1980; Taylor et al. 1983; Quistorff et al. 1993; Wackerhage et al. 1998; Crowther et al. 2002a,b) . Quistorff et al. (1993) did not detect any accumulation of HMP during ischaemic recovery, from which they concluded that glycogen phosphorylase must be regulated in concert with glycolysis. This hypothesis was later refuted by results reported by Crowther et al. (2002a,b) , who found that glycolytic flux was silenced despite a significant increase in HMP (>3 mM). Instead, these results indicated that the deactivation of glycolytic flux is controlled at one or more sites downstream of glycogenolysis. Our results confirm the findings of Crowther et al. (2002a,b) . Moreover, our computational analysis of metabolite concentrations in resting skeletal muscle, validated by reproduction of the HMP dynamics, has identified, for the first time, the most likely sites of this regulation (i.e. PFK and PK) as well as the physiological significance of these controls for the skeletal muscle resting state. Specifically, the simulations suggest that the inactivation of PFK and PK in non-contracting muscle is necessary for cellular metabolite concentration control by preventing depletion of ADP and P i and associated negative effects on other cellular processes, including mitochondrial ATP synthesis. Furthermore, glycolytic intermediates, such as G1P, G6P, F6P, F-1,6P 2 and dihydroxyacetone-phosphate, would also be depleted, affecting fluxes through other branches of the glycolytic pathway (e.g. glycogen production and glycerophospholipid metabolism; glycine, serine and threonine metabolism; and fructose and mannose metabolism). The precise mechanisms involved in the rapid deactivation of PFK and the slower deactivation of PK in skeletal muscle indicated by the present study to occur in the postexercise state remain, however, to be elucidated.
Model limitations
All of the above discussion should be viewed in the context of the limitations of the model simulations. In the process of developing computational models, very often model parameterization is based upon data obtained from different species and/or cell types (e.g. Wu et al. 2007; Cortassa et al. 2003; Nguyen & Jafri, 2005) . Here, we have dealt with this problem numerically by performing Monte Carlo simulations to probe the effect of small changes in parameter values on simulation results. A further improvement can be made by determining the glycolytic enzyme kinetic parameters of human quadriceps muscle. In addition, incorporation of knowledge on the pH dependency of these enzyme kinetics (Vinnakota et al. 2006) would also further improve the basis for the generated hypothesis. Specifically, the NMR data provide quantitative information on in vivo muscle pH dynamics that can be used in the computations. With the present model we were not able to exploit these data. Finally, the numerical analysis indicated that additional PFK and PK deactivation must be present to explain the recorded HMP dynamics. The present model could not be used to reveal the precise biochemical implementation of this deactivation. As in the section 'Model adaptation: PFK inhibition' , the numerically identified hypothesis relates to the work of others indicating a potential role for Ca 2+ -mediated binding of PFK to the cytoskeleton. However, it cannot be ruled out that other (unknown) metabolic feedback loops, not included in the model, may also contribute to the predicted magnitude of PFK and PK deactivation. Experimental identification of these control loops and addition of this information into future models can be used to gain quantitative insight into the relative contribution of these feedback loops to the deactivation mechanisms.
Conclusion
In summary, in vivo magnetic resonance spectroscopy revealed a large accumulation of hexose monophosphates during exercise and a subsequent slow turnover during metabolic recovery. Computational modelling was used to relate these experimental observations to the control mechanisms of the underlying metabolic pathways. Following this approach, the experimental observations were translated into a new hypothesis that silencing of glycolysis in skeletal muscle tissue involves inactivation of both PFK and PK.
